Abstract 155P
Background
Despite the increasing application of robotic surgery in patients with gastric cancer, however, for the complex minimally invasive total gastrectomy, no reports are supporting robotic surgery that can improve surgical performance and clinical outcomes.
Methods
In this prospective study, 50 patients were assigned to underwent robotic total gastrectomy (RTG) between March 2018 to February 2020 at a tertiary referral teaching hospital. Patients who underwent laparoscopic total gastrectomy (LTG) in the FUGES-002 study were matched to compare the surgical outcome and surgery task load of RTG and LTG. Objective structured assessment of technical skill (OSATS) was used to evaluate the technical performance.
Results
After propensity score matching, 48 patients in the RTG group and 96 patients in the LTG group were included in the analysis. The total operative time in the RTG group was longer than that in LTG Group (217.1 minutes vs. 186.1 minutes, P < 0.001). Compared with LTG, the RTG group had less intraoperative blood loss (66.4 ml vs. 38.7 ml, P = 0.042). The average number of errors in the RTG group was 43.2 times/case, which was less than 53.8 times/case in the LTG Group (P < 0.001). Compared with LTG, RTG had a higher OSATS score (30.2 vs. 28.4, P < 0.001). RTG is superior to LTG in terms of respect for tissue, time and motion, instrument handling, and knowledge of specific procedures. The mean number of lymph nodes (LNs) retrieved in the RTG group and LTG group was 47.9 and 44.0, respectively. Significantly more extraperigastric LNs were retrieved in the RTG group than in the LTG group (20.2 vs. 17.5, P = 0.039). RTG group had a lower Surg-TLX score than LTG Group (33.2 vs. 39.8, P < 0.001). The postoperative recovery processes in the RTG group were shorter than those in the LTG Group. No significant difference was found between the RG and LG groups in the incidence (14.6% vs 16.7%, P = .86) or severity of complications.
Conclusions
In the complex radical gastrectomy, compared with traditional laparoscopic surgery, the use of the robotic system provides a technically superior operative environment and lower surgeon workload for minimally invasive surgery.
Clinical trial identification
NCT03524287.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session